Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation

The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
David J CastleTamas Treuer

Abstract

To compare the effectiveness of intramuscular (IM) olanzapine and typical IM antipsychotics in naturalistically treated acutely agitated patients with schizophrenia or acute mania. During the acute phase, 2011 inpatients (including emergency settings) were assessed at 2, 24 and 72 h, and 7 days following initial injection and on oral antipsychotic transition. Mean change in agitation was assessed via Positive and Negative Symptom Scale-Excited Component (PANSS-EC) and Clinical Global Impressions-Severity (CGI-S) scores. Response (> or = 40% reduction in baseline PANSS-EC score) was analysed using logistic regression. Significantly greater decreases in PANSS-EC and CGI-S scores were observed in patients receiving IM olanzapine (n = 1294) as their first injection compared with patients receiving other IM antipsychotics (n = 717) (P<0.05; 2 h: effect size 0.1); IM haloperidol treatment (all assessments, P<0.05); and IM zuclopenthixol treatment (2 h, P<0.001). Higher response rates were observed with IM olanzapine compared with other IM antipsychotics at 24 and 72 h, and 7 days (P<0.05). IM olanzapine was associated with fewer extrapyramidal side effects compared with other assessed IM antipsychotics. IM olanzapine provided somewha...Continue Reading

References

Jan 1, 1990·Schizophrenia Bulletin·S R Kay, S Sevy
Jul 1, 1969·Health Physics·N Ohen, T J Kneip
Nov 30, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·R L Binder, D E McNiel
Apr 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karena M MeehanAlan Breier
Mar 15, 2005·General Hospital Psychiatry·Horacio PrevalAndrew Francis
May 16, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·L SanV Pérez
Apr 3, 2007·Annals of General Psychiatry·Chris J BusheMathew Mathew
Sep 11, 2007·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Jeffrey DanielDavid Castle

❮ Previous
Next ❯

Citations

Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jul 14, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·E PerrinUNKNOWN OBS-IM investigators group
Feb 26, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Marina GarrigaEduard Vieta
Apr 18, 2018·International Clinical Psychopharmacology·Monika EdlingerAlex Hofer
Sep 3, 2013·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Peter BosanacDavid Castle
Mar 8, 2019·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Leonardo BaldaçaraTeng C Tung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.